Aug 11, 2020 / 01:30PM GMT
Operator
Good afternoon, ladies and gentlemen, and welcome to the Epigenomics AG Study Results Conference Call. (Operator Instructions)
Let me now turn over the floor to your host, Mr. Frederic Hilke. Go ahead, please.
Frederic Hilke - Epigenomics AG - IR Officer
Thank you very much, Julia. Hello, and welcome to the conference call. Today, we will discuss the recent publication in the Journal of the National Cancer Institute titled Comparing the Cost Effectiveness of Innovative Colorectal Cancer Screening Tests. My name is Frederic Hilke. I'm the Investor Relations Manager for Epigenomics. With me here on the phone is the CEO of Epigenomics AG, Greg Hamilton; and Dr. Jorge Garces, Epigenomics President and Chief Scientific Officer.
Before I hand over the presentation to Greg, let me point out some of the usual legal information. The following presentation will contain expressly or implicitly certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other
Epigenomics AG - Special Call Transcript
Aug 11, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers